ANI Pharmaceuticals (ANIP) EBITDA margin US GAAP (year values) |
|||||||||
2019 | 2020 | 2021 | 2022 | 2023 | LTM ? | CAGR 5 years ? | |||
EBITDA margin, % | ? | 29.4% | 13.7% | 6.82% | 10.1% | 22.5% | 19.4% | ||
Changes by years, y/y, % | -5pp | -16pp | -7pp | +3pp | +12pp | -8.0% |
ANI Pharmaceuticals. EBITDA margin, %
ANI Pharmaceuticals. EBITDA margin, changes, pp
ANI Pharmaceuticals (ANIP) EBITDA margin US GAAP (quarter values) |
||||||||
2023Q2 | 2023Q3 | 2023Q4 | 2024Q1 | 2024Q2 | LTM ? | |||
EBITDA margin, % | ? | 24.1% | 23.2% | 18.2% | 21.6% | 14.7% | 19.4% | |
Changes by years, y/y, % | +20pp | +6pp | -2pp | -3pp | -9pp | |||
Changes by quarters, q/q, % | -1pp | -1pp | -5pp | +3pp | -7pp |